Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Phase III RUBY Clinical Trial Shows Jemperli Could Redefine Cancer Treatment
GSK today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating […]
NHS Slashes Longest Elective and Cancer Patient Waiting Lists
The number of people waiting over 18 months for NHS care has fallen again despite […]
FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval
The United States Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to […]
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
Incyte today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved […]
Novartis Trial Shows Benefit in Patients with Breast Cancer
Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III […]
EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis
EVERSANA, a leading provider of commercialization services to the life science industry, today announced a […]
Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer
Bayer further expands the global clinical development program for NUBEQA (darolutamide) in prostate cancer. The […]
Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
Massive Bio, a private AI-enabled oncology startup that provides virtual and in-person concierge services for […]
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
Fusion Pharmaceuticals, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more